PDL BioPharma's European Patent Claims Upheld

"PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced that the Opposition Division of the European Patent Office decided today at an oral proceeding to uphold claims in the company's European Patent No. 0 451 216 ('216 patent) that are virtually identical to the claims remitted to the Opposition Division by the Board of Appeal. The patent covers the production of humanized antibody light chains that contain amino acid substitutions made under PDL's antibody humanization technology and provides specific coverage for our daclizumab antibody."